Singapore's GIC leads $260m Series B round in Chinese biopharma firm CStone

Singapore's GIC leads $260m Series B round in Chinese biopharma firm CStone

Photo by Martin Lopez from Pexels

09 May, 2018

6 Dimensions Capital ARCH Venture Partners Boyu Capital CITIC PE CStone Pharmaceuticals GIC Pte Hillhouse Capital King Star Capital Oriza Seed Venture Capital Sequoia China Taikang Insurance Yunfeng Capital

Printed by Unregistered user on Sun, 07 Dec 2025 19:29:14 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Read more from Greater China

Alibaba to retire Ele.me brand amid instant-retail push

HongShan aims for $2.9b sale of Golden Goose to Permira by Christmas: report